Nigeria's pharmaceutical manufacturers are shifting their financial strategies amid soaring borrowing costs and currency instability. With the Central Bank of Nigeria's Monetary Policy Rate at 26.5 percent and commercial lending rates for manufacturers often exceeding 30 percent, companies are finding it increasingly difficult to sustain operations funded by short-term loans. The sector, where production cycles are long and over 70 percent of raw materials are imported, faces a growing mismatch between cash flow needs and available liquidity. Patrick Ajah, managing director of May & Baker Nigeria Plc, stated that loan interest rates as high as 33 percent make it nearly impossible to break even, especially in capital-intensive areas like active pharmaceutical ingredient (API) production.
Firms are now restructuring balance sheets to reduce reliance on expensive debt. Fidson Healthcare Plc raised approximately N21 billion through a rights issue in early 2026, which its managing director Biola Adebayo described as a critical milestone for growth and market positioning. The funds will support expansion, technology upgrades, and operational efficiency. Neimeth International Pharmaceuticals Plc, having returned to profitability in 2025, is extending loan tenors and planning a capital raise to reduce financing costs and strengthen working capital. Valentine Okelu, Neimeth's managing director, noted the restructuring provides more operational room.
Despite a VAT waiver on 875 pharmaceutical raw materials, import dependence and foreign exchange volatility continue to strain input costs, prompting a broader strategic shift away from short-term bank financing.
Patrick Ajah's blunt assessment that 33 percent interest rates make break-even impossible cuts to the heart of Nigeria's industrial financing crisis—manufacturers are being priced out of growth by a financial system that treats long-term production like short-term speculation. The fact that even established firms like May & Baker, Fidson, and Neimeth are scrambling to restructure reveals how deeply high interest rates have undermined the viability of domestic pharmaceutical manufacturing.
This shift is not just about finance—it reflects a deeper failure to align monetary policy with industrial development. With over 70 percent of raw materials imported and the naira under pressure, rising input costs collide with prohibitive lending rates, forcing companies to divert cash flow from production to debt servicing. The N21 billion raised by Fidson through a rights issue underscores investor willingness to support local capacity, but also highlights the inadequacy of bank financing in a high-rate environment. The VAT waiver on 875 pharmaceutical inputs, while helpful, does little to offset structural financing gaps.
For ordinary Nigerians, this squeeze translates into continued reliance on imported medicines, unstable drug prices, and weakened access to essential treatments. Patients, especially those managing chronic conditions, face uncertainty as local production struggles to scale under financial duress. Regions with limited healthcare infrastructure will feel this most acutely.
This story fits a long-standing pattern: Nigerian industries are being asked to build long-term value using short-term, high-cost capital—a model that consistently fails.
